We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Blood Test to Measure Omega-3 Fatty Acids Could Help Evaluate Cardiovascular Risks

By LabMedica International staff writers
Posted on 13 Oct 2023

The human body can produce many of the fats it requires, but omega-3 fatty acids must come from our diet. More...

These essential fatty acids, specifically EPA and DHA, are mainly found in sources like fish, seafood, and certain enriched foods and supplements. A deficiency in these fatty acids can increase cardiovascular risks and is linked to issues like inflammation, mental decline, depression, and problems in fetal brain development and premature births. Currently, assessing omega-3 levels in the blood is challenging and involves an invasive blood test. Now, researchers have come up with a more convenient method to monitor these crucial fatty acids in the blood, making it easier to collect vital health data related to cardiovascular and cognitive health.

Researchers at McMaster University (Hamilton, ON, Canada) have identified a new biomarker for the Omega-3 Index (O3I) which makes it simpler to study the role of omega-3 fatty acid nutrition for overall public health, including among at-risk populations. Traditional methods for assessing O3I have involved drawing significant amounts of blood and complex lab procedures, making it an uncommon practice among healthcare providers. This new technique could enable regular screening, assisting both doctors and patients in determining the appropriate level of supplementation.

Generally, an O3I lower than 4% signifies a greater risk for cardiovascular issues, while an O3I above 8% suggests a lower risk. Importantly, the O3I can be modified through dietary changes. In the study, subjects were administered between 3 to 5 grams of fish oil, EPA, or DHA supplements daily. The research team conducted lipid profiling to pinpoint specific O3I biomarkers from the hundreds of lipids that can be found in the blood. The researchers are also working on identifying a substitute biomarker for the O3I through a urine test, which would eliminate the need for blood draws altogether.

“Our test can be part of a routine blood test without any special requirements,” says lead author Philip Britz-McKibbin, a professor of chemistry and chemical biology at McMaster. “By directly measuring only two specific biomarkers in a blood sample, we can rapidly assess the Omega-3 Index without time-consuming and costly sample workup protocols prior to analysis.”

Related Links:
McMaster University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Drug Testing Assays
Atellica DT 250 Analyzer
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.